A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910